Ads
related to: Psoriasis Treatment- Request A Representative
Request A Rep To Provide Info About
A PSO Biologic Treatment Option.
- Sign Up To Learn More
Visit The HCP Site To Sign Up For
Excusive Updates And Resources.
- Find Dosing & Admin Info
Learn About Loading And Maintenance
Doses For A Psoriasis Treatment.
- Get Safety Profile Info
Learn About The Safety Of A
Plaque Psoriasis Injection Option.
- View Patient Testimonials
Watch A Biologic-Experienced
Patient Testimonial Video.
- A Different Anti-TNF
Discover The Molecular Structure Of
Fab' Biologic. Watch An MOA Video.
- Request A Representative
Search results
Mitochondrial Dysfunction & Chronic Fatigue: Key Takeaways From ‘The Human Upgrade’
The New York Observer· 6 days agoThe May 9 episode (How to Double Your Energy!) of Dave Asprey’s podcast, The Human Upgrade, focused on understanding and overcoming chronic fatigue by enhancing mitochondrial function. Guest ...
Journey Medical Corp Announces New Journey with the Experts Video Featuring Karan Lal, DO
Digital Journal· 5 days agoDr. Lal sits down with Journey Medical to discuss keloids, including what they are, why they occur, and how those affected can seek treatment from their local dermatology ...
MoonLake Immunotherapeutics’ (MLTX) Buy Rating Reiterated at Needham & Company LLC
ETF DAILY NEWS· 4 days agoNeedham & Company LLC reissued their buy rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) in a research report sent to investors on Wednesday morning, Benzinga reports ...
AbbVie Inc. (NYSE:ABBV) Receives $174.31 Average Target Price from Brokerages
ETF DAILY NEWS· 3 days agoShares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the thirteen research firms that are presently covering the stock, MarketBeat ...
Brokers Offer Predictions for AnaptysBio, Inc.’s Q1 2025 Earnings (NASDAQ:ANAB)
ETF DAILY NEWS· 1 day agoAnaptysBio, Inc. (NASDAQ:ANAB – Free Report) – Investment analysts at Wedbush issued their Q1 2025 earnings per share estimates for AnaptysBio in a research report issued on Thursday, May 9th ...
Almirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% Overall and 18% in the European...
Benzinga· 2 days agoPositive trajectory with Net Sales increase by 6.6% to a total of €247.4 MM, EBITDA increase of 1.4% YoY to a total of €52.5 MM driven by higher overall sales Performance driven by biologics as key growth engines,
Ads
related to: Psoriasis Treatment